The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats

The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As anti-inflammation factor most potent vasodilator, CGRP holds therapeutic potentials for treatment of cardiovascular diseases which was, however, limited by its nature short half-life. With advantages in improving stability, circulation time protection from degradation, nanoparticles were promising as delivery carriers peptide. Nevertheless, few nanoparticulate systems developed deliver modulation or functions instead neural regulation. In this study, was encapsulated into poly (lactic-co-glycolic acid) (PLGA) nanoparticle sustained release vivo. recovered systemic level factors CGRP+/? rats comparing administration (Dulbecco's Phosphate Buffered Saline) DPBS only. decrease wall thickness attenuation T cell infiltration lung, polymer based system showed facilitate effects may help development CGRP-based therapy disorder related diseases.